Find the right treatment sooner
ASPYRE-Lung provides answers in days not weeks
Unlocking the promise of precision medicine
Thanks to remarkable advances in precision medicine research, there are now dozens of approved targeted therapies for cancer, many of which are far less toxic and more effective than one-size-fits-all treatments like chemotherapy.
Use of these revolutionary therapies requires accurate biomarker testing to determine which patients will likely benefit, however current testing options are either too slow and complex or too limited to effectively guide treatment decisions. As a result, many patients miss out on the opportunity to receive the best possible care.
ASPYRE is a technological breakthrough that overcomes these barriers, increasing access to the information needed to select the best treatment and enabling more patients to benefit from these life-saving therapies.
ASPYRE-Lung: fast, comprehensive
& useful biomarker information
Fast time to results
The long wait for test results is the most significant barrier to identifying the optima treatment plan for patients. Patients often wait 4-5 weeks to receive results from comprehensive next-generation sequencing (NGS) tests — an unbearably long time when dealing with a devastating cancer diagnosis.
ASPYRE provides results in days, ensuring that patients can receive optimized treatment plans far more quickly.
NGS tests cost as much as $8,000, and many health insurers are reluctant to reimburse them due to the enormous amount of additional information they provide that does not correlate directly with approved therapeutics.
ASPYRE quickly provides comprehensive clinically useful information at a fraction of the cost of NGS, significantly reducing out-of-pocket costs.
Current genomic biomarker testing methods either provide too little or too much information, making it difficult for either option to effectively guide treatment decisions.
With its ability to provide information on alterations across multiple genes, ASPYRE delivers clinically useful results without overwhelming the decision process.
ASPYRE’s ultra-sensitive technology can detect biomarkers from very small amounts of blood or tissue, which may avoid the need for additional biopsies and prevent delays in treatment.
Frequently asked questions
What can I learn from an ASPYRE-Lung test result?
ASPYRE-Lung is a molecular diagnostic test that identifies biomarkers within cancer cells to identify mutations which may provide potential options for you and your doctor to consider in your treatment:
- Therapies you may be eligible for: We identify FDA-approved targeted therapies or immunotherapies that may help you based on the mutations and biomarkers found in your cancer. These therapies have been approved for non-small cell lung cancer (NSCLC).
- Actionable information: ASPYRE-Lung has been thoughtfully designed exclusively for NSCLC patients. The good news is that there are now over 25 targeted therapies available for patients with lung cancer. The ASPYRE-Lung panel includes only those genes that have direct correlation with NSCLC targeted therapies. This simplifies and speeds up the treatment decision process.
How long will it take to receive my test result?
What types of samples can be sent in for the ASPYRE-Lung test?
When should I get an ASPYRE-Lung test if I have been diagnosed with lung cancer?
Does insurance cover my ASPYRE-Lung genomic test?
What is the process for sending a sample to Biofidelity?
What types of samples can be sent in for a solid tumor cancer diagnosis?
What are some reasons why I may not be able to get results after my sample is sent in?
After we receive your sample in our lab, we go through a series of detailed checks to make sure we can return results to your doctor. For tissue samples, we check that there is enough tumor material and tumor DNA in the sample. For all tests, we have additional quality checks before we can issue results.
If we are not able to get results, we will let your doctor know so that a different sample can be sent in. For a tissue test, this could be a different tissue sample or a blood sample. For a test on blood, this could be a redraw. We are committed to working with you and your doctor to find the best chance for getting results to help guide your care.
Is there a charge if results cannot be obtained?
Will I get a copy of my report?
How is my information used?
Your health information may be used and disclosed for treatment, payment, healthcare operations, and other purposes permitted or required by law. Biofidelity may also use your health information to create and use “de-identified” datasets and provide these datasets to biopharma partners, academic researchers, and other third parties to help identify new and better treatments and to advance our understanding of how cancer treatments work. De-identified datasets means that information that could be used to identify a specific individual is removed.
Your de-identified information may be aggregated with thousands of other patients’ de-identified information to generate insights essential to accelerating new discoveries in cancer treatment and ultimately enabling better patient care. However, Biofidelity respects the individual rights of its patients, including a right to opt out of disclosure of their de-identified information to third parties for future research purposes. Any de-identified information already included in a dataset created prior to your opt-out will not be impacted. If you would like to opt out, please contact firstname.lastname@example.org.